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Abstract. 
 
MHC class I proteins assemble with peptides 
in the ER. The peptides are predominantly generated 
from cytoplasmic proteins, probably by the action of 
the proteasome, a multicatalytic proteinase complex. 
Peptides are translocated into the ER by the transport-
ers associated with antigen processing (TAP), and bind 
to the MHC class I molecules before transport to the 
cell surface. Here, we use a new functional assay to 
demonstrate that peptides derived from vesicular sto-
matitis virus nucleoprotein (VSV-N) antigen are ac-
tively secreted from cells. This secretion pathway is de-
pendent on the expression of TAP transporters, but is 
independent of the MHC genotype of the donor cells. 
Furthermore, the expression and transport of MHC 
class I molecules is not required. This novel pathway is 
sensitive to the protein secretion inhibitors brefeldin A 
(BFA) and a temperature block at 21
 
8
 
C, and is also in-
hibited by the metabolic poison, azide, and the protein 
synthesis inhibitor, emetine. These data support the ex-
istence of a novel form of peptide secretion that uses 
the TAP transporters, as opposed to the ER translocon, 
to gain access to the secretion pathway. Finally, we sug-
gest that this release of peptides in the vicinity of unin-
fected cells, which we term surrogate antigen process-
ing, could contribute to various immune and secretory 
phenomena.
 
P
 
rotein 
 
secretion has traditionally been thought to
involve the action of the translocon located in the
membrane of the ER of eukaryotic cells. Proteins
are recognized cotranslationally when a signal sequence or
a signal–anchor sequence emerges from the ribosome (Wal-
ter and Johnson, 1994). These sequences are recognized
and bound by the signal recognition particle, and the re-
sulting ribosomal complex then interacts with the signal
recognition particle receptor on the ER membrane at the
translocon (Andrews and Johnson, 1996). This results in
the inclusion of proteins within the secretory pathway.
This pathway is by far the best described route of protein
secretion in eukaryotic cells. Recently, it has been pro-
posed that some proteins are recognized by a component
of the translocon, sec 61, exit the ER, and are transported
into the cytoplasm where they are degraded (Wiertz et al.,
1996).
The translocation into the ER of antigenic peptides for
presentation by major histocompatibility complex (MHC)
 
1
 
class I molecules is largely independent of the translocon.
This form of translocation involves the action of two gene
products that are members of the ATP binding cassette
family. These genes encode transporters associated with
antigen processing 1 and 2 (TAP-1 and -2), and have been
implicated in the translocation of peptides from the cyto-
plasm to the lumen of the ER (Deverson et al., 1990; Bah-
ram et al., 1991; Spies and DeMars, 1991; Spies et al., 1992;
Gabathuler et al., 1994). After translocation into the ER,
antigenic peptides bind to MHC class I molecules com-
posed of a heavy chain (46-kD) and a light chain (12-kD)
called 
 
b
 
2
 
m (Nuchtern et al., 1989; Yewdell and Bennink,
1989; van Bleek and Nathenson, 1990; Matsumura et al.,
1992), before transport to the cell surface. The assembly
and transport of MHC class I molecules appears to be reg-
ulated by a series of chaperones that includes calnexin
(Degen and Williams, 1991), calreticulin, and tapasin (Sa-
dasivan et al., 1996).
High performance liquid chromatography analysis of
peptides eluted from acid-treated whole cells or MHC
class I molecules has allowed the identification and char-
acterization of the peptides associated with MHC class I
molecules (Falk et al., 1990; Rötzschke et al., 1990; van
Bleek and Nathenson, 1990). It is proposed that MHC
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class I molecules determine the final identity of MHC-
restricted peptides and have an instructive role, in addition
to a selective role, in peptide selection (Wallny et al., 1992).
MHC binding to larger peptides followed by protected
proteolytic trimming is a possible mechanism that could
account for the observed MHC dependency of cellular
peptides (Falk et al., 1990). Peptides unable to bind MHC
class I because they are in excess or lack the correct MHC
binding motif for the MHC haplotype are thus far unde-
tectable by the techniques commonly used in the field, and
are presumed to be short lived and degraded (Falk et al.,
1990; Rötzschke et al., 1990). Recent results, however, sug-
gest that peptides not able to bind to a MHC class I mole-
cule intracellularly may be found bound to heat shock pro-
teins (HSPs) such as gp96 (grp94; Arnold et al., 1995). These
authors show that cellular antigens are represented by
peptides associated with gp96 molecules independently
of the MHC class I expressed, confirming earlier results
(Udono and Srivastava, 1993, 1994). Gp96 extracted from a
specific cell is able to induce cross-priming (Udono and
Srivastava, 1993, 1994). Finally, two studies have demon-
strated that peptides transported into the lumen of the
ER, and do not bind to MHC class I molecules, can be
transported out of the ER into the cytoplasm again by a
process called “efflux” (Momburg et al., 1994; Schumacher
et al., 1994), which may involve the action of the TAP mol-
ecules or the sec 61 protein associated with the translocon
(Wiertz et al., 1996).
We have developed a new bioassay to test the hypothe-
sis that peptides translocated into the ER by the action
of the TAP molecules become secreted. Using this assay,
we present evidence of an alternative secretion pathway
that exists in various mammalian cell types. These obser-
vations revise the model of peptide catabolism, and may
provide an explanation for various immune and secretion
phenomena.
 
Materials and Methods
 
Cell Lines and Cell Culture
 
RMA and RMA-S (H-2b) cell lines (Kärre et al., 1986) are maintained in
culture in RPMI-1640 medium (GIBCO BRL, Gaithersburg, MD), sup-
plemented with 10% heat-inactivated FBS, glutamine, penicillin, strepto-
mycin, and Hepes. CMT.64 (H-2b), a small cell lung carcinoma cell line
(Jefferies et al., 1993; Gabathuler et al., 1994), is maintained in DME
(GIBCO BRL) supplemented with 10% heat-inactivated FBS, glutamine,
penicillin/streptomycin, and Hepes. CMT.12-12 are CMT.64 cells trans-
fected with the rat TAP-1 and -2 cDNA (provided by G. Butcher, Agricul-
ture and Food Research Council, Institute of Animal Physiology, Cam-
bridge, UK). CMT.12-12 and L cells (American Type Culture Collection,
Rockville, MD) are grown in DME (GIBCO BRL) with supplements.
R1E (H-2k) cells, R1E expressing K
 
b
 
 and 
 
b
 
2
 
m were provided by D.B. Wil-
liams (Williams et al., 1989).
 
Tissue Culture Infectious Dose Affecting 50% of the 
Cultures (TCID
 
50
 
) Determination
 
Vero cells in 96-well plates were treated with vesicular stomatitis virus
(VSV) preparations collected from the indicated cell lines 72 h after infec-
tion with 10
 
5
 
 TCID
 
50
 
 units of VSV virus (multiplicity of infection [MOI] of
0.01). The plates were monitored for 5 d for cytopathic effect, and then
the final titers were calculated as per TCID
 
50
 
.
 
Vaccinia Virus (VV) Constructs
 
The recombinant VV containing the VSV-N 52–59 peptide gene (VV–
NP) was constructed by first ligating a double-stranded synthetic oligonu-
cleotide encoding the VSV-N 52–59 peptide into a VV shuttle vector pJS5
(provided by B. Moss, National Institutes of Health [NIH], Bethesda,
MD). The oligonucleotide, which contained SacI and NheI overhangs for
ligation into pJS5, is as follows: 3
 
9
 
-tcgag-tac-tct-cct-ata-cag-atg-gtt-ccg-
gag-act-cgatc-5
 
9
 
, with the complementary strand as 5
 
9
 
-c-atg-aga-gga-tat-
gtc-tac-caa-ggc-ctc-tga-g-3
 
9
 
. The VV–NP was then made by homologous
recombination when the pJS5–VSV-N52–59 construct was transfected
into CV-1 cells infected with VV (WR strain provided by S. Gillam, Univer-
sity of British Columbia, Vancouver, Canada). VV–NP was plaque purified
three times in BS-C-1 cells, and then amplified in Hela S3 cells before vi-
rus purification on a sucrose gradient (Earl and Moss, 1992). The shuttle
vector pJS5 without an insert was also cloned into VV (VV–pJS5) to pro-
vide a vector only control. The recombinant VV expressing the VSV-N
52–59 peptide with an NH
 
2
 
-terminal leader sequence of E3/19k (VV–
ESNP) was provided by J. Yewdell (NIH, Bethesda, MD) (Eisenlohr et
al., 1992; Bacik et al., 1994).
 
Virus Infections and Cytotoxic T Lymphocyte
(CTL) Assay
 
CTL effectors were generated by injecting C57Bl/6 mice with VSV (5 
 
3
 
10
 
6
 
 TCID
 
50
 
 per site) behind the ears. 5 d later the draining lymph nodes
were removed, and then lymphocytes were cultured at 4 
 
3
 
 10
 
6
 
 cells/ml for
3 d in the absence of stimulation in RPMI-1640 with 10% heat-inactivated
HyClone FBS (GIBCO BRL), glutamine, penicillin/streptomycin, Hepes,
0.1 mM essential amino acids, 1 mM Na-pyruvate, and 50 
 
m
 
M 2-ME. In
the experiment described in Fig. 6, CTL effectors were generated from
splenocytes. Briefly, spleens from C57Bl/6 VSV-infected mice were ho-
mogenized with a Douncer, and then the splenocytes were pelleted and
washed three times before counting. Splenocytes were kept at 30 
 
3
 
 10
 
6
 
cells per 10 ml medium as described previously. These splenocytes were
kept for 10 d in culture with 1 
 
m
 
M VSV-N 52–59 peptides before the CTL
assay. Cold targets were either treated with VSV (MOI of 2) for 12 h and
subsequently washed, or treated with exogenous peptides (VSV-N 52–59)
and subsequently washed. VV infection of cold targets was done as fol-
lows: VV–NP, VV–pJS5, and VV–ESNP were trypsinized in 0.1 vol 2.5
mg/ml trypsin (1:250; Difco Laboratories, Inc., Detroit, MI) for 30 min at
37
 
8
 
C, with vortexing every 10 min. After washing CMT.64, CMT.12-12,
and L cells with PBS, the virus was added to the cells (MOI of 10), along
with 0.5 ml RPMI supplemented with 2% heat-inactivated FBS, gluta-
mine, penicillin, streptomycin, and Hepes. They were incubated for 1.5 h
at 37
 
8
 
C before adding 3 ml RPMI supplemented with 10% heat-inacti-
vated FBS, glutamine, penicillin, streptomycin, Hepes, and brefeldin A
(BFA; Boehringer Mannheim, Mannheim, Germany) when indicated.
The addition of azide or emetine at the indicated concentration was done
3 h after infection. The temperature block at 21
 
8
 
C was done from 3 h after
infection until the beginning of the CTL assay. The cells were removed
with versene and 0.05% trypsin, and then washed two times with medium
before addition to the CTL assay. The total infection time was 6 h until
the start of the assay, or longer as indicated. Hot targets, which were
RMA cells or as indicated, were treated with [
 
51
 
Cr] for 1 h at 37
 
8
 
C and
subsequently washed. [
 
51
 
Cr] was used at 100 
 
m
 
Ci per 10
 
6
 
 cells. Cold targets
were diluted two- or threefold when indicated, starting with 2 
 
3
 
 10
 
5
 
 cells
per well at a 20:1 ratio cold/hot targets. Each well received 10
 
6
 
 effector
CTL and 10
 
4
 
 hot targets (100:1 ratio effector/hot targets). BFA at a con-
centration of 10 
 
m
 
g/ml was added to the assay when indicated. Effectors
plus cold and hot targets were incubated together in V-bottom 96-well
plates for 4 h for radioactivity release. In some assays, cold targets are re-
placed by medium containing peptides or viruses where indicated. The su-
pernatant of VSV-infected cells was previously desalted through a G-25
column (Pharmacia Diagnostics, AB, Uppsala, Sweden), and then lyoph-
ilized before reconstitution in 2 ml of medium to achieve a 5
 
3
 
 concentra-
tion. The [
 
51
 
Cr] release was measured by an LKB1282CS Compugamma
counter (model 1282CS; LKB Pharmacia, Turku, Finland), and the spe-
cific [
 
51
 
Cr] release calculated as (experimental 
 
2
 
 media control)/(total 
 
2
 
media control) 
 
3
 
 100%. The spontaneous release never exceeded 20% of
the maximum release (treated with 1.5% Triton X-100).
 
Peptide Translocation Assay
 
Streptolysin-O–mediated transport assays were performed as described
previously (Momburg et al., 1994) with minor modifications. Briefly, a
peptide library was designed with a tyrosine for radioiodination and an
N-glycosylation site on each peptide. The peptide library was 
 
125
 
I-labeled
by chloramine T-catalyzed iodination to a specific activity of 10 Ci/mmol
(Heemels et al., 1993). 10
 
6
 
 cells treated or not with 10 
 
m
 
g/ml of BFA were 
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permeabilized with 2 IU/ml of streptolysin-O (bioMerieux, Marcy-
l’Etoile, France) for 10 min at 37
 
8
 
C. The iodinated peptide library (
 
z
 
66
ng) was added, and then the incubation was continued for 10 min in the
presence or absence of 10 mM ATP (Sigma Chemical Co., St. Louis, MO).
The cells were then transferred to ice, lysed in a buffer containing 1%
Nonidet P-40, 150 mM NaCl, 5 mM MgCl
 
2
 
, 50 mM Tris-HCl, pH 7.5, and
then the nuclei were removed by centrifugation at 14,000 rpm for 10 min.
Translocated peptides that had been glycosylated in the ER were recov-
ered by adsorption to concavalin A–Sepharose beads (Pharmacia Diag-
nostics, AB). The beads were washed five times in lysis buffer, and then
the associated radioactivity was measured in a LKB1282CS Com-
pugamma counter (model 1282CS; LKB Pharmacia).
 
BFA, Azide, and Emetine Treatment and
Temperature Block
 
BFA was used at a concentration of 10 
 
m
 
g/ml. BFA treatment of cold tar-
gets was started at the same time as the VSV infection at a MOI of 2, or
for the last 4 h of infection before incubation with hot targets and effector
CTL. BFA was kept in the CTL assay at a diluted concentration of 2 
 
m
 
g/ml
that did not affect CTL recognition. BFA was added 
 
z
 
2 h after the start
of the VV–NP or VV–ESNP infection, and then kept at 10 
 
m
 
g/ml through-
out the infection and the assay or as indicated. The peptide translocation
assay was done after overnight treatment of the cells with 10 
 
m
 
g/ml of BFA.
Azide, a metabolic poison, was added to VV–NP–infected L cells from
the start or 3 h after the start of the infection at a concentration of 50 mM,
and then removed by washing before the CTL assay. Emetine (Sigma
Chemical Co.), a protein synthesis inhibitor, was added to VV–NP–infected
L cells 3 h after the start of the infection at a concentration of 10 or 50 
 
m
 
M,
and then maintained or washed before the CTL assay. The temperature
block at 21
 
8
 
C was done for 3 h after a 3-h VV–NP infection of L cells un-
til the beginning of the CTL assay. Exposure of the cells to 21
 
8
 
C would
otherwise inhibit the infection of the cells or the CTL assay.
 
Results
 
The binding of peptides with MHC class I heavy chain and
 
b
 
2
 
m within the lumen of the ER has been well docu-
mented. However, alternative fates for peptides trans-
ported into the ER may exist. One such possibility is the
expulsion of the peptide from the cell via the secretory
pathway. To determine whether peptides transported into
the ER are subsequently secreted from the cell, we have
developed a novel assay in which the CTL-mediated lysis
of uninfected cells provides a readout of the ability of vi-
rally infected cells to transfer sensitizing peptide. This was
achieved by incubating virally infected cells with chro-
mium (Cr)-loaded uninfected cells. Virus-specific CTL are
then added to the culture, and any resulting Cr release is
measured. In the absence of peptide transfer, the levels of
release would be minimal. Fig. 1 (
 
A
 
) clearly shows that sig-
nificant levels of lysis of the uninfected RMA cells (Kärre
et al., 1986) are achieved after incubation with VSV-infected
RMA cells, strongly suggesting that specific viral peptides
had been transferred from the infected cells. We have used
uninfected Cr-loaded RMA cell killing as a readout sys-
tem because RMA cells are more sensitive to exogenous
peptides than other cell lines under the conditions of our
experiment. However, we are able to observe the same
phenomenon when using Cr-loaded RMA-S and CMT.64
cells as recipients (data not shown).
To determine whether peptides shed from cell surface
MHC class I complexes contributed to this transfer, we
made use of the fact that in the context of an H-2K
 
b
 
 re-
sponse, 
 
.
 
90% of CTL recognize a single immunodomi-
nant epitope of the VSV-N protein (VSV-N 52–59; van
Bleek and Nathenson, 1990; Zhang et al., 1992). Our re-
sults using cold target competition assays (Kulkarni et al.,
1993), indicate that the peptide transferred is indeed VSV-N
52–59 (data not shown). Uninfected RMA cells were
pulsed with a high concentration of VSV-N 52–59 peptide,
and then the ability of these cells to sensitize Cr-loaded
uninfected cells was measured (Fig. 1 
 
A
 
). We find that cells
pulsed with saturating concentrations of antigenic peptide
are not able to efficiently transfer peptides to recipient
cells. Although this may happen over time, as suggested by
Huang et al. (1994), we find no evidence for this in our as-
says. The inefficiency of cells pulsed with exogenous pep-
tides to sensitize target cells for CTL killing suggests that
transferred peptides do not originate from peptide–pro-
tein complexes present on the cell surface (Srivastava et al.,
1994). Importantly, this assay indicates that the occurrence
of classical bystander killing in this system is negligible.
We further used the existence of the single immuno-
dominant epitope to calculate approximate concentrations
of peptide transferred to recipient cells. Fig. 1 (
 
B
 
) shows
Figure 1. Specific CTL rec-
ognition after peptide trans-
fer to uninfected RMA cells
from VSV-infected RMA
cells. (A) Peptide transfer oc-
curs after viral infection but
not after pulsing with syn-
thetic viral peptide. Hot tar-
gets were RMA cells and
cold targets were diluted
twofold, starting with 2 3 105
cells per well at a 20:1 ratio
to cold/hot targets. [51Cr] re-
lease was calculated as indi-
cated in Materials and Meth-
ods. Black, striped, and white
bars represent RMA1VSV,
RMA1p, and RMA1- - -, re-
spectively. (B) A Peptide-
RMA cell dose–response
curve allows approximation of the amount of peptide transferred from virally infected cells. RMA cells were incubated with different
concentrations of the VSV-N peptide in presence of cold and hot RMA targets during 4 h. Striped bars represent RMA. 
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the dose-response curve obtained when a mixture of cold
and Cr-loaded RMA cells, mimicking the conditions of the
transfer assay, are pulsed with different concentrations of
peptide. When VSV-infected RMA cells (Kärre et al., 1986)
are used as the peptide donors, we obtain 25% lysis of the
uninfected cells at an infected/uninfected ratio of 20:1
(Fig. 1 
 
A
 
). Comparison with the dose-response curve (Fig.
1 
 
B
 
) suggests that this level of lysis represents exposure of
the uninfected cells to 
 
z
 
5–50 nM of peptides. It must be
stressed that this can only be an approximation because of
the kinetics of the viral infection that contrast with the
static concentrations achieved by adding exogenous peptide.
It was important to determine if the peptide transfer we
observed could be explained by viral killing or CTL-medi-
ated release of peptides from infected cells. By altering the
parameters of VSV infection, we clearly demonstrate that
the time course of the assay (4 h) does not allow Cr-loaded
cells to be infected with VSV, process and degrade the
proteins, and present the VSV-N peptides to specific CTL
(Fig. 2 
 
A
 
). To further address this possibility, we studied
cells that are not recognized by VSV-specific K
 
b
 
-restricted
CTL, but retain their ability to be infected by virus.
CMT.64, T2, Ltk
 
2
 
, and RMA cell lines are infected to a
similar level by VSV (Table I). We show that human T1
(Salter and Cresswell, 1986), and murine Ltk
 
2
 
 (H-2
 
k
 
) trans-
fer peptides to recipient uninfected RMA (H-2
 
b
 
) cells (Fig.
2 
 
B
 
). However, none of these cell lines is recognized and
lysed by VSV-specific K
 
b
 
-restricted CTL (Fig. 2 
 
C
 
), which
contrasts to RMA cells (Fig. 2 
 
A
 
). This result again dem-
onstrates that we do not measure classically defined by-
stander killing of cells in our assay (Tite and Janeway,
1984; Tite et al., 1985, 1986). The difference in transferring
ability among cells with various MHC haplotypes (Fig. 2 
 
B
 
)
could be because of competition with the endogenous K
 
b
 
binding activity in H-2
 
b
 
 cells (Fig. 1 
 
A
 
), or simply because
different cell lines secrete different amounts of peptide
(Fig. 2 
 
B
 
). Furthermore, when cells with the same MHC
haplotype (H-2
 
b
 
) are used in the assay, cold competition
for CTL recognition decreases the relative cytolysis (Fig.
1 
 
A
 
). In addition, this experiment indicates that the ability
to transfer the relevant peptide is not dependent on the
MHC class I molecules expressed by the VSV-infected cells.
Figure 2. CTL and viral lysis do not mediate peptide transfer. (A) Pep-
tide sensitization is not because of VSV infection of Cr-loaded cells.
RMA cells were infected for 12 h with VSV as previously described
(RMA1VSV), or alternatively, RMA cells were treated with VSV imme-
diately before adding the effectors (RMA.41VSV). The effector to target
(E:T) ratios ranged from 12.5:1 to 100:1. Black, striped, and white bars
represent RMA1VSV, RMA1---, and RMA.41VSV, respectively. (B)
Peptide transfer from infected to uninfected cells is independent of the
MHC haplotype of the cell infected by VSV and not dependent on
CTL-mediated release. A human T1 cell line and the mouse Ltk2 (L)
were treated with or without (L1---) VSV (MOI of 2) for 12–18 h as de-
scribed previously. RMA cells were used as hot targets as described pre-
viously. Black, striped, and white bars represent T11VSV, L1VSV, and
L1---, respectively. (C) VSV-infected T1 and Ltk2 were not recognized
by CTL used in the assay. T1, Ltk2 (L) cells were added to effectors af-
ter VSV infection and [51Cr] labeling to examine whether or not they
are recognized as targets for VSV-specific CTL at different effector to
target ratios (E:T). Mock infected Ltk2 cells (L1---) were used as nega-
tive controls. Black and striped bars represent T11VSV and L1VSV,
respectively.Gabathuler et al. Transporter-dependent Antigenic Peptide Secretion 21
To establish the significance of individual components
of the antigen processing pathway for peptide transfer, we
investigated whether cell variants deficient in one or more
elements of this pathway are able to transfer peptide. Hu-
man T2 (Salter and Cresswell, 1986), and murine CMT.64
(H-2b), cells (Jefferies et al., 1993; Gabathuler et al., 1994)
do not express either TAP-1 or -2. After infection with
VSV, we find that these cell lines are neither recognized
by VSV-specific Kb-restricted CTL (Jefferies et al., 1993;
data not shown), nor are they able to efficiently transfer
peptides to the recipient RMA cells (Fig. 3 A). As shown
above, the wild-type T1 cells, though not recognized by
VSV-specific CTL (Fig. 2 C), are able to transfer a VSV
peptide (Fig. 2 B). CMT.64 cells induced with IFN-g to ex-
press TAP-1 and -2 are able to transfer peptides (Fig. 3 A).
Furthermore, CMT.64 transfected with the rat TAP-1 and
-2 genes (CMT.12-12) are able to transfer a peptide to
RMA cells (Fig. 3 A). These data reveal a dependency on
the expression of the TAP transporters for the exchange
of peptide(s). This infers that the peptides must be translo-
cated into the ER to be transferred.
To investigate whether interaction with and transport by
MHC class I molecules is a prerequisite for peptide trans-
fer, we used the murine R1.E (H-2k) cells (Williams et al.,
1989) that lack b2m, and therefore do not transport MHC
class I heavy chain. R1.E cells are able to efficiently trans-
fer peptides to RMA cells (Fig. 3 B). The contribution of
Kb molecules alone, and of Kb and b2m to this peptide
transfer was established by examining R1.E cell deriva-
tives transfected with heavy or heavy and light chains. The
expression of Kb alone and both Kb and b2m does not af-
fect the efficiency of peptide transfer of transfected R1.E
cells (Fig. 3 B). This indicates that peptide binding and
transport of MHC class I molecules is not required for
transfer of the peptide.
The role of the secretory pathway in peptide transfer
was studied using BFA, an inhibitor of protein secretion.
BFA was used at concentrations reported previously (Nuch-
tern et al., 1989; Yewdell and Bennink, 1989; Jefferies et al.,
1993), which effectively inhibit protein secretion in these
cells, but do not harm cell viability (data not shown). BFA-
treated RMA cells were infected with VSV, and then ex-
amined for their ability to transfer peptide to recipient
cells. We find that BFA dramatically inhibits peptide trans-
fer (Fig. 4 A), suggesting that the peptide must be actively
transported through the secretory pathway for efficient
transfer to take place. To confirm that BFA did not simply
inhibit CTL recognition, different concentrations of BFA
from 4–10 mg/ml were added directly to a CTL assay, and
then the effects were monitored (Fig. 4 B). It is clear from
these data that VSV-specific CTL recognition of peptide-
pulsed targets (RMA cells) was not affected by BFA. There
are no significant differences between CTL lysis and pres-
ence or absence of BFA in the effector/target ranges of
100:1 to 0.046:1 (Fig. 4 B). To determine that BFA does
not merely inhibit peptide translocation and that the ob-
served effects are truly on the secretory pathway, BFA
was used in the well-established in vitro peptide transport
assay. The peptides were designed with an iodination site
(Tyr) and an N-glycosylation site (Heemels et al., 1993),
which permits ER translocation to be assessed by the ac-
Table I. TCID50 Results: 106 Cells Infected with VSV at a MOI 
of 0.1*
Cell line Titer
Exp. 1 Exp. 2
CMT 64 9.6 3 106 5.4 3 108
RMA 1.2 3 107 7.2 3 108
T2 9.3 3 106 6.2 3 108
Ltk2 1.1 3 107 8.1 3 108
*The cell lines used in this assay were approximately the same in their ability to re-
produce VSV.
Figure 3. Examination of antigen processing components re-
quired for peptide transfer. (A) TAP transporter dependency of
peptide transfer. Hot targets were RMA cells treated as previ-
ously described. Cold targets serving as peptide donors consisted
of RMA, CMT.64 1/2 IFN-g (CMT and CMT.IFN, respec-
tively), and CMT.64 cells transfected with the rat TAP-1 and
TAP-2 genes (CMT.12-12). These cells were treated with VSV
(MOI of 2) for 12–18 h, and then subsequently washed three
times. (B) Peptide transfer is independent of b2-microglobulin and
MHC class I transport. Hot targets were RMA cells treated as
previously described. Cold targets consisted of R1E cells and
their derivatives R1E transfected with Kb (R1EKb), and R1E
transfected with b2m, and Kb (R1EKbb2). Cold targets were
treated with or without (R1EKbb21---) VSV (MOI of 2) for
12–18 h, and then subsequently washed three times.The Journal of Cell Biology, Volume 140, 1998 22
quisition of N-glycans on radioiodinated peptides. Semi-
permeabilized RMA-S or RMA cells were incubated with
synthetic peptides in the presence and absence of ATP,
and then their translocation was monitored. RMA-S cells
do not translocate the peptide in this assay, likely because
of the absence of the TAP-2 subunit of the TAP complex
(Fig. 4 C). The addition of ATP does not alter the peptide
transport in these cells. The RMA cells, on the other hand,
do actively translocate the peptide in the presence of ATP
(Fig. 4 C), demonstrating that translocation is TAP and
ATP dependent. RMA cells incubated overnight in the
presence of 10 mg/ml of BFA, which inhibits peptide trans-
fer, are equally or slightly elevated in their ability to trans-
locate the peptides. Again, this process is ATP dependent
(Fig. 4 C). These data demonstrate that peptide transfer is
dependent on the secretory pathway and TAP-mediated
translocation.
Our observation that growth medium from Ltk2 cells in-
fected with VSV, collected before virally induced lysis, can
sensitize uninfected RMA cells for CTL recognition (Fig.
5), confirms that peptides are secreted by VSV-infected
cells. In addition, this result indicates that contact between
the donor and recipient cells is not necessary for sensitiza-
tion of target cell for CTL lysis.
We sought to demonstrate that the life cycle of VSV was
not in some way specifically leading to the release of the
VSV-N 52–59 peptide. We addressed this issue by creating
a recombinant VV encoding the VSV-N 52–59 peptide. In
the initial experiment, Ltk2 cells (H-2k) were infected with
either VSV, VV, or VV encoding VSV–NP 52–59, and then
assayed for their ability to transfer the VSV-N peptide to
recipient cells (Fig. 6 A). Clearly, only VSV itself and the
VV–NP construct are able to transfer the peptide to RMA
cells. The activities of both viruses are titratable, and the
VSV appears to be more efficient than the recombinant VV
at providing peptides for transfer. These data demonstrate
that in a heterologous system, VSV-N peptide expression
results in peptide transfer. It also demonstrates once again
that it is not dependent on the expression of the H-2b hap-
lotype. Furthermore, this data also demonstrates that an
eight-amino acid peptide is sufficient for transfer, indicat-
ing that it is not dependent on extracellular cleavage
events. To investigate the TAP dependency of peptide
transfer in the heterologous expression system, we in-
fected CMT.64 or CMT.64 expressing TAP-1/2 (CMT.12-
12) with the VV–NP peptide or with the wild-type VV (Fig.
6 B). These results clearly demonstrate the TAP depen-
dency of the transfer of VSV-N peptide expressed in a het-
erologous system. These data confirm that the peculiari-
ties of the VSV life cycle do not contribute to the peptide
transfer mechanism. To confirm that the secretory path-
way is again involved in peptide transfer involving the ex-
pression of the VSV-N peptide in a heterologous system, L
cells, CMT.64 cells (TAP negative), and CMT.12-12 cells
(expressing TAP-1 and -2) were infected with the VV ex-
pressing the VSV peptide, and then the peptide transfer
was monitored (Fig. 6 C) in the presence or absence of
BFA. In cells lacking TAP expression (CMT.64 cells), no
Figure 4. BFA inhibition
demonstrates the depen-
dency of peptide transfer on
the secretory pathway. (A)
BFA inhibits peptide trans-
fer in VSV-infected RMA
cells. Hot targets were RMA
cells treated as previously de-
scribed. Cold RMA cells
were treated with BFA at
10 mg/ml from the start of
the VSV infection (RMA1
BFA1VSV), only for the
last 4 h of the VSV infec-
tion (RMA1VSV1BFA), or
without BFA at 10 mg/ml
(RMA1VSV). VSV infection
was done for 12 h at a MOI
of 2. BFA was kept in the as-
say during incubation with
effector CTL at a diluted
concentration of 2 mg/ml.
Black,  striped, and grey bars represent RMA1BFA1VSV, RMA1VSV1BFA, and RMA1VSV,
respectively. (B) BFA treatment does not inhibit the CTL-dependent lysis of target cells. Hot targets
were RMA cell-pulsed (RMA1p) or not (RMA), with VSV-N 52–59 peptide at a concentration of 1
mM. BFA was added in the assay during incubation with effector CTL at a concentration indicated (4,
5, or 10 mg/ml). (C) BFA does not affect the TAP-dependent peptide translocation in the ER. Cells as
indicated treated or not with BFA (10 mg/ml) were permeabilized with streptolysin-O, and then used
to monitor the ER translocation of radioiodinated peptides in presence (ATP) or absence (control) of
ATP. The protocol is described in Materials and Methods. The radioactivity in counts per minute is
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peptide transfer was observed in BFA-treated or -untreated
cells. This is consistent with the TAP dependency of these
processes observed previously. Conversely, the peptide
transfer process of the TAP-expressing cells (L and
CMT.12-12 cells) was grossly inhibited by the presence of
10 mg/ml of BFA. In addition, emetine, which inhibits pro-
tein synthesis (Braciale et al., 1988), and azide, which in-
hibits respiratory metabolism, were used to demonstrate
that this process was energy- and protein synthesis depen-
dent, and was not a result of general cell deterioration be-
cause of virus-induced cell death. Emetine was shown (Fig.
6 D) to be an excellent inhibitor of the process when incu-
bated with the donor cells demonstrating that protein syn-
thesis is required and, moreover, peptide secretion is an
active process. Similarly, azide (Fig. 6 E) is able to inhibit
this process, and shows that energy metabolism is required
for the secretion of the peptides that sensitize recipient
target cells. Temperature reduction to 218C has been shown
to block protein secretion (Matlin and Simons, 1983; Kuis-
manen and Saraste, 1989), and its effects were examined
on the peptide transfer process. Temperature block before
incubation with CTL clearly affects the peptide transfer
process (Fig. 6 D). The data demonstrates that the block-
age is not complete, and this is likely because of the fact
that the temperature block must be released to incubate
the cells with the CTL in this assay. Thus, some sensitiza-
tion is expected. These data demonstrate surrogate anti-
gen processing is dependent on TAP translocation, secre-
tion, and energy, and on de novo protein synthesis.
As a final confirmation that a novel route of entry into
the secretory pathway had truly been identified, it was rea-
soned that the TAP dependency of this pathway could be
bypassed by the addition of a signal sequence to the NH2-
terminus of the VSV-N peptide. This peptide should enter
the secretory pathway via the translocon, and thus bypass
the TAP translocation process. A VV construct containing
the E3/19k signal sequence (Eisenlohr et al., 1992; Bacik
et al., 1994) was obtained (a gift of J. Yewdell), and pep-
tide transfer was monitored in TAP-expressing (L cells) and
-nonexpressing cells (CMT.64) infected with this recombi-
nant VV (VV–ESNP) or with the recombinant VV con-
taining the VSV-N peptide without the signal sequence
(VV–NP; Fig. 7 A). In L cells that express TAP molecules,
both the peptide with and without the signal sequence are
able to be transferred. The VSV peptide without the signal
sequence is slightly more efficient; this could be because of
the greater activity of the TAP translocator versus the
translocon, or simply because of the heterogeneity in ex-
pression levels between the two recombinant viruses. These
data contrast with that obtained in cells lacking TAP mol-
ecules (CMT.64 cells). Expression of the peptide contain-
ing the signal sequence results in its transfer in the absence
of the TAP molecules, whereas the peptide lacking a sig-
nal sequence is not able to be transferred from these cells.
These data demonstrate that the secretory pathway, which
has been identified, is distinct from that involving the
translocon, and that the new secretory pathway involves
translocation by the TAP molecules.
To demonstrate the BFA sensitivity of the peptide
transfer process involving the translocon secretory path-
way, BFA was added to the assays and its effects were ob-
served (Fig. 7 B). Peptide transfer from the cells express-
ing the VSV-N peptide containing the signal sequence is
clearly affected in TAP-expressing and -nonexpressing
cells. These data demonstrate that peptide transfer can
take place through the translocation of peptides via the
translocon if the signal exists in the peptide to do so. These
data also suggest that it is the initial translocation event in-
volving the translocon or TAP complexes that controls the
peptide transfer process, and the rest of the secretory path-
way may be shared by the two translocators.
Discussion
Here we show that endogenously produced antigenic pep-
tides have alternative fates within the cell. Not only can
peptides bind to MHC class I molecules and be trans-
ported through the cell to the cell surface, they can also be
secreted independently of MHC class I molecules from the
cell. This secretion appears to be dependent on TAP-
based translocation into the ER, and is BFA sensitive.
Therefore, the normal secretory pathway is important for
this process. Data from other laboratories (Falk et al.,
1990; Rötzschke et al., 1990; Wallny et al., 1992) suggest
that peptides, once generated, are able to bind to MHC
class I molecules in the lumen of ER, and they speculate
this protects them from total degradation. On this basis, an
instructive role for MHC class I molecules in cellular pep-
tide processing has been postulated (Wallny et al., 1992).
Recently, new results (Arnold et al., 1995) have shown an
alternative fate for antigenic peptides that do not bind self-
MHC class I molecules. These peptides are found bound
to HSPs, like gp96, and were previously undetectable in
these cells. Furthermore, other work has demonstrated
that peptides transported into the lumen of the ER can be
transported out of the ER and back into the cytosol by a
Figure 5. Peptide transfer from cell supernatants demonstrates
that cell to cell contact is not required. Supernatants from Ltk2
cells infected with VSV or mock treated were collected 12 h after
infection and treated as described in Materials and Methods. The
supernatant was then added to [51Cr]-laden RMA cells, and the
resulting CTL mediated lysis was measured. Black and grey bars
represent L-VSV and L---, respectively.The Journal of Cell Biology, Volume 140, 1998 24
process referred to as an efflux (Momburg et al., 1994; and
Schumacher et al., 1994). It is possible that these peptides
could bind to proteins like gp96 and then be protected
from degradation. Our results show that peptides that do
not bind to MHC class I molecules, either because they
are made in excess or because the cells lack the MHC class
I molecules capable of binding the VSV peptide, are se-
creted from the cell. Thus, in a situation in which there are
high concentrations of peptides produced, the equilibrium
can be pushed towards either secretion of the unbound
Figure 6. VSV-N 52–59 peptide encoded by the VV is able to be transferred and sensitize uninfected
RMA cells in a TAP-dependent manner using the secretory pathway. (A) Peptide transfer occurs af-
ter infection with a recombinant VV encoding the VSV-N 52–59 peptide and is MHC haplotype inde-
pendent. Hot targets were RMA (H-2b) cells and cold targets were diluted threefold starting with 2 3
105 cells per well at a ratio of 20:1 cold/hot targets. Cold targets were Ltk2 (H-2k) cells (L) infected
with the wild-type VV, or the recombinant VV encoding VSV-N 52–59 peptide (VV–NP). Effector
CTL were from splenocytes cultured and used at a ratio effector/target of 100:1 as indicated in Mate-
rials and Methods. [51Cr] release was calculated as indicated in Materials and Methods. (B) VSV-N
52–59 peptide encoded by the VV is transferred in a TAP-dependent manner. The same protocol as
described above was used. The cells were infected at a MOI of 10 for both viruses, 6 h before CTL as-
say. CMT.64 (CMT) and CMT.12-12 (CMT1.2) infected with wild-type VV and recombinant VV (VV–NP) were used as cold targets.
(C) The transfer of VSV-N 52–59 peptide encoded by the VV is inhibited by BFA, an inhibitor of the secretory pathway. The same pro-
tocol as described above was used. BFA was added z2 h after infection of L cells (L), CMT.64 (CMT), and CMT.12-12 (CMT1.2) cells
with the recombinant VV (VV–NP). These cells were used as cold targets. In addition, BFA at 10 mg/ml was added directly in the assay.
(D) Emetine, a protein synthesis inhibitor, and a low temperature (218C), inhibit the transfer of VSV-N peptide. The same protocol for
infection as described above. Emetine was added during the last 3 h of VV–NP infection of L cells (3h), and in the CTL assay when in-
dicated (7h) at a concentration of 10 and 50 mM. The temperature block at 218C was done after transfer of VV–NP–infected L cells from
378 to 218C for the last 3 h of infection only. The treated cells were used as cold targets in the CTL assay. (E) Azide, a metabolic poison,
inhibits the VSV-N peptide transfer. The same protocol for infection as described above. Azide was added at a concentration of 50 mM
from the start (6h) or for the last 3 h (3h) of VV–NP infection of L cells. The treated cells were used as cold targets in the CTL assay.
Solid bars represent L1VV–NP; narrow striped bars represent L1VV–NP 1 Azide 6 h; wide striped bars represent L1VV–NP 1 Azide 3 h.Gabathuler et al. Transporter-dependent Antigenic Peptide Secretion 25
peptide, or return of the peptide to the cytoplasm, which
presumably results in further degradation. It is speculated
that the return of the peptide to the cytoplasm involves the
TAP transporters, but it could involve the recently de-
scribed translocon function involving sec 61 that exudes
some fraction of MHC heavy chains to the cytoplasm (An-
drews and Johnson, 1996; Wiertz et al., 1996).
Overall, the pathway we describe is a hitherto unknown
pathway for peptide secretion that does not involve the
translocon for translocation into the ER, but relies upon
the TAP transporters for ER delivery. The limitations for
this transport mechanism are likely to be the size and com-
position of the peptides that can be transported by the
TAP molecules. Clearly, the specificities of the TAP mole-
cules from different species and different TAP alleles
within a species would alter the type of peptides delivered
to the ER. Additionally, the affinity of the MHC molecule
for a peptide could contribute to its secretion. The size of
the peptides that could conceivably be secreted by this
mechanism would be limited by the size of peptides trans-
ported by the TAP molecules. Furthermore, the broader
specificity of action of the TAP transporters as compared
to the binding of the MHC molecules may result in a pool
of peptides that could also be secreted in this way, but do
not have the ability to bind to MHC molecules. This could
result in secretion of small peptides that could function in
processes not involving MHC molecules.
The phenomenon we describe differs from the previous
observations (Arnold et al., 1995), where gp96 and HSPs
are ER resident or cytosolic proteins, and under normal
circumstances not released from cells. Gp96 with bound
peptides must be extracted from homogenized cells. It is
even possible that peptides become bound to gp96 during
the extraction process. In our case, secretion from live cells
allows peptides to become associated with the MHC class
I molecules expressed on the cell surface of surrounding,
uninfected cells. We do not know in which form the pep-
tide is secreted: it may be bound to a carrier protein, for
example. A thorough characterization of the medium con-
taining the sensitizing peptide is needed to identify such a
protein. It is unlikely that these secreted peptides would
have been detected in previous extraction protocols used
in the field.
To support the model of peptide secretion, it was crucial
to exclude a role for virally induced or CTL-mediated lysis
as a source of priming peptide. To achieve this, many of
our assays utilized CTL that do not recognize the virally
infected cell type used. Furthermore, one would not ex-
pect a dependency on TAP expression if peptides were
transferred by viral lysis per se. Additionally, the virus ti-
tre produced by these different cell lines was similar, also
demonstrating no TAP dependency for VSV infection. Al-
though the phenomenon we describe is dependent on
TAP-mediated translocation into the ER and general pro-
tein secretion, it is not specifically reliant on MHC trans-
port. The possibility that the VSV-N peptide is somehow
unique because of its potentially high affinity for Kb is un-
likely to provide an explanation: a high affinity for Kb
would drive the equilibrium towards assembly with MHC
heavy chain rather than secretion; yet, we easily detect it.
It is interesting to note that Huang et al. (1994) have eluci-
dated mechanisms in which proteins or peptides may ei-
ther be exchanged from donor to recipient after release
from the cell surface or released after uptake of antigen by
the antigen processing donor. Though these phenomena
may operate under specific circumstances, they relate to
the processing of exogenous antigens rather than the en-
dogenous antigens we examine here. Furthermore, not-
withstanding complete protease digestion of small pep-
tides to amino acids, peptide secretion seems a reasonable
fate for peptides that enter the secretory pathway. It will
be of great interest to examine this phenomenon in other
systems and to determine whether other proteins, such as
carrier proteins, are required for peptide secretion.
Our results using a VV construct expressing the VSV-N
peptide epitope demonstrate clearly that the peptide trans-
Figure 7. VSV-N 52–59 peptide is translocated in the ER inde-
pendently of TAP expression when expressed with a signal se-
quence and further secreted by the secretory pathway. (A) VSV-N
peptide is transferred independently of TAP expression if tar-
geted to the secretory pathway by a signal sequence. The same
protocol as described in Fig. 6 was used. L cells (L) and CMT.64
cells (CMT) were infected with recombinant VV expressing the
VSV-N peptide (VV–NP) or the VSV-N peptide with a NH2-ter-
minal signal sequence (VV–ESNP), and were used as cold tar-
gets. (B) BFA inhibits the transfer of VSV-N peptide targeted to
the secretory pathway by a signal sequence. The same protocol as
described in Fig. 6 was used. L cells (L), CMT.64 (CMT), and
CMT.12-12 (CMT1.2) cells were infected with the recombinant
VV expressing VSV-N 52–59 peptide with a NH2-terminal signal
sequence (VV–ESNP). BFA was added z2 h after the infection,
and then added in the assay at 10 mg/ml.The Journal of Cell Biology, Volume 140, 1998 26
fer is not the result of the VSV replication pathway. The
VV-encoded peptide (VSV-N 52–59) also requires a func-
tional TAP transporter, strongly supporting the view that
the normal antigen peptide processing machinery is re-
quired. In addition, these data demonstrate that the 8-amino
acid peptide itself can be transferred, and transfer is thus
not dependent on the proteolytic cleavage of a larger frag-
ment extra- or intracellularly. Furthermore, peptide trans-
fer of the VV-expressed VSV-N peptide is also BFA sensi-
tive and has the same characteristics as the VSV-expressed
peptide. To address the temperature, energy, and secre-
tory dependency of this process, inhibitory methods were
used. Emetine inhibits protein synthesis (Braciale et al.,
1989), and clearly inhibits surrogate antigen processing
(Fig. 6 D). Likewise, azide also inhibits energy metabolism
and ablates peptide transfer (Fig. 6 E). Furthermore, a
cold temperature (218C) block (Matlin and Simons, 1983;
Kuismanen and Saraste, 1989) that inhibits protein secre-
tion also inhibits peptide transfer (Fig. 6 D). The data pre-
sented here, and confirmed by all of the controls described
above, demonstrate the dependency of this process on en-
ergy metabolism, de novo synthesis, and protein secretion.
Thus, these data and controls conclusively show that this
phenomenon is not because of a trivial release of peptide
by dead cells. Overall, peptide transfer is not dependent
on VSV infection nor the viral lytic cycle. Finally, we dem-
onstrated that peptides containing a signal sequence can
bypass the TAP-dependent translocation event and use
the classic translocon for entrance into the lumen of the
ER. Once there, the pathway for peptide transfer is BFA
sensitive. These data suggest the TAP molecules regulate
access to the peptide secretory pathway of peptides lack-
ing signal sequences, but that the translocon regulates the
access of signal sequence-containing peptide to the secre-
tory pathway. Therefore, the downstream components of
the secretory pathway may be shared by both transloca-
tors. The interpretation that this is a new secretory path-
way is based on our assertion that protein translocation
across the ER membrane is an initial event in secretion,
and our evidence demonstrating that peptides transported
by the TAP complex can be secreted illustrates a hitherto
unknown mechanism for gaining access to the downstream
components of the secretory pathway.
The peptide transfer phenomenon we have described in
vitro represents a hitherto undescribed fate for antigenic
peptides. It will be of great interest to determine if this is
indeed a general phenomenon relevant to many peptides.
If this is the case, it is intriguing to speculate that peptide
secretion may play a role in some currently poorly under-
stood phenomena, such as pathogen-induced autoimmunity,
where viral infection in one anatomical location results in
tissue damage in another (Sinha et al., 1990). Additionally,
it may account for mechanisms of rejection of organs on
the basis of minor histocompatibility type and cross-prim-
ing phenomena (Bevan et al., 1976; Gooding and Ed-
wards, 1980; Huang et al., 1994; Huang et al., 1996). Lastly,
this mechanism could account for T cell selection in the
thymus in the absence of thymic cells expressing the se-
lecting antigen.
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